Market Outlook
By 2032, the U.S. Endoscopy Devices Market is projected to reach approximately USD 26.85 billion, expanding at a CAGR of 8.31% during the forecast period 2027–2032. The market stood at USD 16.64 billion in 2026, following historical values of approximately USD 13.12 billion in 2023, USD 14.18 billion in 2024, and USD 15.35 billion in 2025. Values in this report are expressed in USD billions.
The U.S. endoscopy devices industry operates at the strategic nexus of minimally invasive surgical innovation, optical physics, video sensor miniaturization, artificial intelligence-driven diagnostic software, infection prevention mandates, and clinical ambulatory migration. Market momentum is driven by an aging demographic with escalating rates of gastrointestinal cancers, urological obstructions, chronic pulmonary diseases, and degenerate musculoskeletal disorders. In 2024, more than 22.4 million screening and diagnostic gastrointestinal endoscopies were performed across American healthcare facilities, supported by revised United States Preventive Services Task Force guidelines lowering the baseline colorectal screening age to 45. Concurrent expansions in surgical laparoscopy, arthroscopy, and bronchoscopy elevated total annual endoscopic procedure volumes beyond 75 million interventions nationwide.
Clinical workflow economics across human health systems are permanently altering equipment acquisition parameters. Hospital surgical and endoscopy suites face persistent margin pressures stemming from fixed reimbursement structures under the Centers for Medicare and Medicaid Services Outpatient Prospective Payment System and Ambulatory Surgical Center payment frameworks. Healthcare leadership prioritizes endoscopic platforms that shorten operating room turnover intervals, mitigate perioperative complication risks, eliminate scope-related nosocomial cross-contamination events, and interface directly with hospital-wide picture archiving and enterprise electronic health record platforms. Capital acquisitions are rigorously evaluated against clear total cost of ownership models that account for device purchase prices, multi-year preventive service contracts, reprocessing labor burdens, chemical sterilization overhead, and single-use transition economics.
The rapid escalation of outpatient surgical migration has redistributed procedural volume from traditional inpatient hospital operating rooms to specialized ambulatory surgery centers and independent endoscopy suites. Approximately 64% of all screening colonoscopies, outpatient ureteroscopies, and diagnostic arthroscopies are currently executed in outpatient ambulatory facilities. This structural relocation of care demands differentiated device form factors, favoring versatile, compact, energy-efficient visualization towers, ultra-portable chip-on-tip visualization systems, and high-throughput automated endoscope reprocessors designed to maximize daily procedure capacity while maintaining strict clinical compliance.
Concurrently, the historical reliance on fully reusable flexible endoscopes has transitioned into a sophisticated dual-tier modality model. The persistent clinical challenge of multidrug-resistant pathogen transmission associated with complex elevator mechanisms in reusable duodenoscopes and bronchoscopes accelerated the market entry of single-use, fully disposable architectures and modular hybrid scopes featuring disposable end-caps. Regulatory safety alerts issued by the U.S. Food and Drug Administration, alongside updated reprocessing standards from the Association for the Advancement of Medical Instrumentation, have forced hospital value analysis committees to systematically reconsider the recurring labor, microbiological culturing, and legal liabilities inherent to manual scope decontamination. Device manufacturers have captured substantial value by engineering single-use scopes that deliver diagnostic image quality rivaling multi-thousand-dollar reusable platforms, eliminating sterilization cycles entirely.
The historical period from 2023 through 2025 was marked by acute clinical catch-up post-pandemic, widespread capital fleet modernization, the rapid replacement of aging standard-definition video towers with native 4K and ultra-high-definition imaging platforms, and the commercial rollout of real-time computer-aided polyp detection software modules. From 2027 onward, market expansion will be heavily driven by next-generation single-use endoscopes, cloud-integrated artificial intelligence diagnostics, advanced surgical visualization incorporating indocyanine green fluorescence imaging, robotic-assisted endoluminal navigation platforms, and smart endotherapy instrumentation capable of performing complex organ-preserving tissue resections.
Introduction
According to the U.S. Endoscopy Devices Market Report, endoscopic medical technology represents one of the most critical and commercially lucrative domains within the American healthcare delivery landscape. Minimally invasive diagnostic and interventional endoscopy has transformed patient management across internal medicine, surgical oncology, general surgery, gastroenterology, pulmonology, urology, gynecology, and orthopedics. A patient traversing modern clinical care pathways routinely encounters endoscopic technologies at multiple intervention points: presenting for early outpatient cancer screening utilizing optical chromoendoscopy and artificial intelligence mucosal inspection, undergoing interventional tissue staging via endoscopic ultrasound and fine-needle biopsy, or receiving curative endoluminal resections utilizing high-frequency electrosurgical knives and automated clip closures.
This clinical continuum generates a highly resilient, multi-tiered commercial ecosystem characterized by large capital hardware investments paired with recurring, high-margin consumable and service revenue streams. Capital visualization towers, video processors, light engines, and automated reprocessing infrastructure establish an installed base within operating suites and endoscopy units. Meanwhile, flexible and rigid endoscopes, hand instrumentation, electrosurgical accessories, biopsy snares, single-use access trocars, and specialized single-use scopes generate predictable, high-velocity procedural cash flows. Device economics across the American healthcare sector are shaped by third-party payer reimbursement structures. Hospital outpatient prospective payments, ambulatory surgery center fee schedules, and physician fee relative value units govern procedural profitability, compelling medtech vendors to design devices that measurably accelerate procedure completion, reduce anesthesia duration, and minimize post-procedure adverse events.
The rapid evolution of optical and sensor engineering has unlocked unprecedented clinical precision at the point of care. The integration of complementary metal-oxide-semiconductor image sensors directly onto distal scope tips, known as chip-on-tip technology, has largely supplanted fragile optical fiber bundles in flexible endoscopes. Distal chip-on-tip architectures eliminate optical transmission loss, maximize light sensitivity, and enable wide-angle visualization fields exceeding 170 degrees. Concurrently, light-emitting diode and laser diode illumination engines have reduced operating temperatures, eliminated costly xenon bulb replacement cadences, and unlocked multi-wavelength optical modalities such as narrow band imaging, linked color imaging, and blue light visualization. These advanced spectral modalities allow endoscopists to visualize microvascular architecture and mucosal surface morphology with microscopic clarity, drastically elevating the clinical detection rates of early dysplasia and flat pre-cancerous lesions.
Clinical practice economics within American hospitals are fundamentally altered by workforce dynamics and sterile processing capacity constraints. Sterile processing departments face severe shortages of trained instrumentation technicians, creating operational bottlenecks in manual pre-cleaning, leak testing, automated chemical reprocessing, and dry-channel storage of complex flexible endoscopes. Reprocessing failures introduce catastrophic infection risks, including transmission of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa. These operational realities have catalyzed explosive demand for single-use endoscopes, particularly in high-risk, rapid-turnaround clinical applications such as emergency bronchoscopy in intensive care units, difficult endotracheal intubations in emergency departments, and urgent ureteroscopies. In parallel, reusable device vendors are redesigning scope architectures to incorporate sterile disposable elevator caps, detachable distal components, and seamless flush channels, optimizing reprocessing efficacy while maintaining the premium handling mechanics preferred by interventional subspecialists.
The technological frontier is further characterized by the confluence of endoluminal visualization and robotic-assisted surgical platforms. Robotic bronchoscopy systems utilizing shape-sensing fiber-optic navigation have revolutionized pulmonary nodule evaluation, allowing interventional pulmonologists to traverse tortuous peripheral airways and biopsy sub-centimeter lung lesions with pinpoint spatial accuracy. Similar robotic advancements are entering endoluminal gastrointestinal surgery, enabling bimanual endoscopic submucosal dissection, full-thickness gastric resection, and endoluminal suturing through natural orifices. These robotic and digitally assisted platforms expand clinical indications, reduce patient trauma, and convert complex inpatient surgical interventions into safe, outpatient procedures.
From 2027 through 2032, commercial competition in the United States will center on connected, intelligent, and infection-resistant clinical ecosystems. Leading medical device conglomerates are expanding beyond standalone optical hardware to deliver integrated digital suites. These suites unite multi-modality visualization, edge artificial intelligence diagnostic algorithms, enterprise PACS archiving, automated scope inventory management utilizing radio-frequency identification tracking, and nationwide rapid-exchange fleet support contracts. Market leadership will belong to manufacturers that deliver superior optical performance, ironclad infection prevention compliance, measurable procedural time savings, and seamless integration across enterprise hospital and independent ambulatory surgery center networks.
Key Market Drivers: What’s Fueling the U.S. Endoscopy Devices Market Boom?
The primary catalyst driving the expansion of the U.S. endoscopy devices market is the demographic aging of the American population and the concurrent surge in chronic disease incidence requiring endoscopic diagnosis and intervention. By 2030, all baby boomers will be older than 65, expanding the Medicare-eligible population to more than 73 million individuals. Advancing age is the single greatest risk factor for gastrointestinal malignancies, gastroesophageal reflux disease, Barrett’s esophagus, biliary tract disorders, benign prostatic hyperplasia, bladder cancer, degenerative joint diseases, and chronic obstructive pulmonary diseases. The clinical imperative to detect malignancies at asymptomatic, early stages has elevated routine endoscopic screening into a foundational public health priority. The lowering of the baseline screening age for colorectal cancer from 50 to 45 by the U.S. Preventive Services Task Force, the American Cancer Society, and the American Society for Gastrointestinal Endoscopy added approximately 19 million eligible adults into the regular screening pool, driving sustained capital and consumable demand across inpatient hospital endoscopy departments and outpatient endoscopy facilities.
A second major growth driver is the continuous transition of surgical and diagnostic interventions from open procedures and inpatient hospital stays toward outpatient minimally invasive surgery and ambulatory surgery centers. Payers, hospital networks, and surgical specialists are aligned in shifting clinical volume toward lower-cost outpatient care environments that provide superior operational efficiency and higher patient satisfaction. Endoscopic and laparoscopic techniques dramatically reduce surgical tissue trauma, intraoperative blood loss, postoperative pain, opioid consumption, and patient recovery durations. The Centers for Medicare and Medicaid Services has actively encouraged this procedural migration by expanding the list of covered surgical procedures payable in ambulatory surgery centers, including complex spine decompressions, joint arthroscopies, and advanced laparoscopic interventions. Ambulatory surgery center administrators are actively investing in dedicated 4K laparoscopic towers, integrated smoke evacuation systems, flexible chip-on-tip endoscopes, and compact high-throughput automated endoscope reprocessors to accommodate expanding caseloads and maximize suite utilization.
A third driver is the regulatory, clinical, and liability pressure surrounding flexible endoscope reprocessing and healthcare-associated infections. Over the past decade, documented clinical outbreaks of multidrug-resistant pathogens linked to improperly reprocessed flexible endoscopes—specifically duodenoscopes used in endoscopic retrograde cholangiopancreatography and bronchoscopes used in critical care—have resulted in intense scrutiny from the Food and Drug Administration, the Centers for Disease Control and Prevention, and hospital accreditation bodies. The publication of updated Association for the Advancement of Medical Instrumentation standards, notably ANSI/AAMI ST91:2021, established rigorous, resource-intensive requirements for manual cleaning verification, channel inspection using borescopy, automated chemical reprocessing, and dry-air channel storage. These demanding requirements have dramatically increased the operational cost and labor complexity of maintaining reusable endoscope fleets. Consequently, health system leadership has rapidly accelerated the procurement of sterile, single-use disposable endoscopes and modular hybrid scopes with single-use distal caps. Single-use devices guarantee sterility, eliminate cross-contamination liability, release sterile processing capacity, and enable instantaneous procedure deployment across emergency departments, operating rooms, and intensive care units.
A fourth growth driver is the clinical convergence of high-definition optical hardware, multi-spectral imaging, and edge artificial intelligence. Artificial intelligence-assisted computer-aided detection and diagnosis systems have transitioned from experimental technologies into indispensable clinical tools. Computer-aided detection algorithms analyze real-time video frames during colonoscopies, placing visual bounding boxes around suspected polyps and lesions, thereby significantly reducing adenoma miss rates. Clinical trials demonstrating substantial increases in adenoma detection rates have compelled gastroenterology practices and ambulatory surgery centers to upgrade existing processor fleets with AI modules to improve clinical quality scores and satisfy payer quality reporting standards. Furthermore, optical chromoendoscopy technologies, such as narrow band imaging, linked color imaging, blue light imaging, and indocyanine green fluorescence, provide real-time superficial microvascular and biliary mapping without requiring systemic tissue dyes, allowing endoscopists and laparoscopic surgeons to execute precise oncological resections with clear margins.
A fifth driver is the technological advancement and clinical expansion of interventional endotherapy and minimally invasive surgical techniques. Diagnostic endoscopy has evolved into advanced therapeutic endoluminal intervention. Complex procedures once requiring extensive open abdominal or thoracic resections—such as endoscopic submucosal dissection, peroral endoscopic myotomy, endoscopic sleeve gastroplasty, transoral incisionless fundoplication, and endoscopic ultrasound-guided biliary drainage—are now routinely executed through flexible endoluminal approaches. These advanced interventional techniques mandate specialized high-precision accessories, including electrosurgical knives, steerable motorized guide wires, lumen-apposing metal stents, automated rotational hemoclips, and endoscopic tissue suturing devices. The high procedural billings associated with complex endotherapy interventions incentivize medical facilities to acquire advanced therapeutic endoscopes equipped with large working channels, auxiliary water jets, and multi-bending distal articulation mechanics.
A sixth growth driver is the ongoing labor crisis and staffing shortage across American surgical nursing and sterile processing departments. Health systems nationwide struggle to recruit, train, and retain certified sterile processing technicians and specialized operating room nurses. Flexible endoscope reprocessing requires meticulous adherence to multi-step protocols that demand considerable physical handling and cognitive attention. High staff turnover elevates the risk of human error, protocol deviation, and scope handling damage, which inflates annual endoscope repair costs. Hospital leadership is increasingly deploying automation to mitigate staffing vulnerabilities. This dynamic drives investment in fully automated endoscope reprocessors equipped with automated chemical dosing, continuous channel flow monitoring, and integrated barcode tracking systems. In high-acuity, unpredictable clinical environments such as intensive care units and trauma resuscitation bays, nursing labor constraints strongly favor the adoption of single-use bronchoscopes and rhinolaryngoscopes that require zero sterile processing overhead and eliminate after-hours technician on-call costs.
Finally, the continuous refinement of robotic-assisted endoscopy and shape-sensing endoluminal navigation systems is expanding the reach and precision of minimally invasive medicine. Robotic navigation systems have gained rapid adoption in interventional pulmonology, where they enable clinicians to navigate deep into peripheral pulmonary anatomy to biopsy small, previously inaccessible lung nodules identified on low-dose computed tomography screening scans. The integration of continuous shape-sensing fiber-optic technology, real-time fluoroscopic overlay, and rigid robotic arm stabilization allows physicians to achieve diagnostic yields exceeding historical standard bronchoscopy benchmarks. The success of robotic pulmonology platforms has spurred substantial capital investment into robotic-assisted gastrointestinal, endovascular, and natural orifice transluminal endoscopic surgical systems, establishing a transformative technological tier within tertiary hospital procurement cycles.
Innovation in Focus: How Manufacturers Are Raising the Bar?
Innovation in the U.S. endoscopy devices market is driving a fundamental shift from standalone mechanical optical instruments to interconnected, intelligent, and infection-resistant digital surgical ecosystems. Medical device engineers are focusing on distal tip sensor integration, broad-spectrum solid-state illumination, machine-learning computer vision, ultra-precision micro-mechanics, single-use high-volume manufacturing, and enterprise data interoperability.
In flexible and rigid endoscopic visualization, the market has transitioned toward native 4K ultra-high-definition imaging, high dynamic range color processing, and distal chip-on-tip complementary metal-oxide-semiconductor sensor architectures. Legacy video systems that relied on complex proximal optical lenses, glass fiber image conduits, and standard-definition charge-coupled devices have been systematically phased out. Distal chip-on-tip sensors place the image capture mechanism millimeters from tissue surfaces, eliminating optical distortion, minimizing thermal generation, and transmitting raw digital signals directly through ultra-thin internal wiring. Advanced video processors utilize wide color gamuts and real-time contrast correction algorithms to deliver crisp structural differentiation, allowing surgeons to distinguish delicate nerve fibers, microvascular capillary networks, and subtle mucosal neoplastic changes with remarkable diagnostic fidelity.
Illumination engineering has undergone a parallel revolution with the displacement of high-maintenance xenon and halogen bulbs by multi-wavelength solid-state light-emitting diode and laser diode light engines. Solid-state illumination eliminates the recurring operating costs, high heat output, and sudden bulb failures associated with xenon arc lamps, offering operating lifetimes exceeding 20,000 hours. Furthermore, multi-LED and laser systems enable instantaneous electronic wavelength switching. By dynamically combining specific narrowband spectra—such as blue and green wavelengths calibrated to the absorption peaks of oxygenated and deoxygenated hemoglobin—modern systems project optical chromoendoscopy images that accentuate surface microvasculature and pit patterns without requiring manual mucosal spraying of indigo carmine or methylene blue dyes.
Artificial intelligence is delivering transformative clinical capabilities through embedded edge computing modules integrated directly into endoscopy processor consoles. Computer-aided detection algorithms analyze live video streams at 60 frames per second, processing tens of thousands of image parameters simultaneously to identify colorectal polyps, non-polypoid flat adenomas, and early esophageal squamous cell carcinomas. When a suspicious lesion enters the visual field, the software projects visual target markers and emits subtle audio cues to alert the endoscopist. Next-generation computer-aided diagnosis modules extend beyond detection to provide real-time optical biopsy analysis, classifying identified polyps as hyperplastic or adenomatous based on microvascular morphology. This real-time histological prediction supports resect-and-discard strategies, significantly reducing pathology processing expenditures for healthcare systems while maintaining uncompromising oncological safety.
The rapid maturation of indocyanine green fluorescence imaging has redefined intraoperative anatomical visualization across laparoscopic and robotic surgical procedures. Modern 4K laparoscopic towers integrate specialized infrared laser illumination and filtering sensors that capture near-infrared fluorescence emissions following intravenous or biliary injection of indocyanine green. This technology enables real-time laparoscopic visual assessment of tissue perfusion, microvascular integrity in intestinal anastomoses, identification of sentinel lymph nodes in oncological dissections, and clear fluoroscopic delineation of extrahepatic biliary anatomy during laparoscopic cholecystectomies. By rendering vital anatomical structures fluorescently visible beneath overlying adipose tissue, near-infrared imaging directly mitigates common surgical errors, such as accidental common bile duct transection and anastomotic ischemic breakdown.
Single-use endoscopic architecture represents one of the most commercially disruptive engineering accomplishments in contemporary medtech. Pioneered in flexible bronchoscopy and urological ureteroscopy, single-use scopes have advanced into complex clinical domains, including duodenoscopes for endoscopic retrograde cholangiopancreatography, echoendoscopes for endoscopic ultrasound, and gastrointestinal enteroscopes. Manufacturers utilize highly automated manufacturing lines, high-precision injection-molded optical lenses, ultra-miniaturized digital image sensors, and cost-effective medical-grade polymers to construct single-use scopes that deliver mechanical steering articulation, channel suction efficiency, and optical resolution comparable to premium reusable devices. These sterile-packaged instruments eliminate the substantial capital investment, maintenance overhead, and reprocessing infection risks of traditional scopes, delivering immediate clinical readiness across intensive care units, emergency departments, and high-throughput ambulatory surgical centers.
Hybrid scope engineering provides a highly pragmatic solution to contamination risks in procedures where fully disposable scopes remain cost-prohibitive or clinically constrained. Manufacturers have engineered modular reusable endoscopes equipped with sterile, single-use distal components and elevator mechanisms. In high-risk interventional procedures such as duodenoscopy, the complex moving elevator mechanism and surrounding crevices represent the primary sites of organic debris entrapment and reprocessing failure. By replacing the permanent elevator with a detachable, single-use sterile cap, clinicians can thoroughly inspect, brush, and reprocess the exposed scope distal tip while utilizing a sterile, mechanically pristine elevator mechanism for every patient. This hybrid paradigm drastically lowers cross-contamination risks while preserving the tactile feedback, optical customization, and torque transmission of high-tier reusable scopes.
Robotic endoluminal navigation platforms combine ultra-flexible catheter mechanics, continuous shape-sensing fiber optics, and motorized micro-drive systems. In interventional pulmonology, robotic platforms utilize integrated fiber-optic sensors that measure light reflection along the entire length of the flexible catheter hundreds of times per second, calculating the exact three-dimensional physical shape and spatial orientation of the scope within the bronchial tree without relying on ionizing radiation. Surgeons control the system through intuitive console joysticks, navigating narrow sub-segmental bronchi with sub-millimeter precision. These platforms provide stable peripheral docking, allowing specialized biopsy needles, cryoprobes, and confocal laser endomicroscopy sensors to access peripheral pulmonary nodules that were previously accessible only through invasive transthoracic needle biopsies or wedge resections.
Segmentation Insights
The U.S. Endoscopy Devices Market is segmented on the basis of product type, usability and architecture, application, technology and modality, and end user.
- By Product Type
The U.S. Endoscopy Devices Market by product type is segmented into Endoscopes, Endoscopic Visualization and Imaging Systems, Operative Equipment and Energy Systems, Endotherapy Instrumentation and Accessories, and Reprocessing and Infection Prevention Systems.
Endoscopes
Endoscopes represent the primary device category, accounting for USD 7.20 billion in 2026, up from USD 5.64 billion in 2023, USD 6.11 billion in 2024, and USD 6.63 billion in 2025. The category is projected to reach USD 11.83 billion by 2032, advancing at an 8.63% CAGR from 2027 to 2032. This extensive segment encompasses rigid endoscopes, flexible endoscopes, capsule endoscopes, and robot-assisted endoscopes utilized across diagnostic and interventional clinical suites.
The sustained revenue dominance of endoscopes is rooted in the continuous clinical necessity of direct anatomical visualization for medical screening, staging, and therapeutic interventions. Rigid endoscopes—including laparoscopes, arthroscopes, and cystoscopes constructed with stainless-steel sheaths and rod-lens optical systems—form the standard visualization tool in general surgery, gynecological procedures, and orthopedic repairs due to their optical clarity, structural rigidity, and long operational lifespans. Concurrently, flexible endoscopes—such as colonoscopes, gastroscopes, duodenoscopes, and bronchoscopes—maintain extensive procedural utilization because their articulating distal tips and flexible insertion shafts navigate complex, tortuous internal anatomy. Procurement behavior in this segment is driven by rapid transitions toward distal chip-on-tip sensors, expanded four-way tip deflection capabilities, wider working channel diameters, and the dual-track adoption of both premium multi-use scopes and single-use disposable devices.
Endoscopic Visualization and Imaging Systems
Endoscopic visualization and imaging systems accounted for USD 3.45 billion in 2026, following historical revenues of USD 2.76 billion in 2023, USD 2.97 billion in 2024, and USD 3.20 billion in 2025. This segment is projected to reach USD 5.46 billion by 2032, expanding at a 7.95% CAGR from 2027 to 2032. Hardware within this category includes dedicated video processors, high-definition camera heads, solid-state LED and laser light sources, ultra-high-definition 4K medical-grade displays, wireless image transmitters, and integrated surgical capture carts.
Capital procurement of visualization towers is governed by the demand for resolution upgrades, high dynamic range color fidelity, and multi-specialty cross-compatibility. Modern video processor consoles serve as the central digital processing hub within the operating room, integrating real-time image enhancement algorithms, digital chromoendoscopy filters, optical zooming controls, and live video streaming gateways. The rapid replacement of legacy high-definition consoles with native 4K UHD systems allows surgical teams to clearly visualize critical anatomical structures, tissue planes, and fine microvasculature. Furthermore, hospital procurement committees favor universal visualization consoles that seamlessly interface with flexible endoscopes, rigid laparoscopes, and specialty arthroscopes, allowing healthcare systems to maximize capital equipment utilization across multiple surgical departments.
Operative Equipment and Energy Systems
Operative equipment and energy systems generated USD 2.35 billion in 2026, rising from USD 1.84 billion in 2023, USD 1.99 billion in 2024, and USD 2.16 billion in 2025. The segment is on track to achieve USD 3.74 billion by 2032, growing at an 8.05% CAGR from 2027 to 2032. This category comprises advanced electronic insufflators, surgical smoke evacuation units, suction and irrigation pumps, electrosurgical generators, advanced bipolar vessel-sealing platforms, and ultrasonic dissection systems.
The continuous expansion of minimally invasive surgery relies directly on advanced operative support hardware to establish and maintain a stable, safe surgical field. Automated high-flow insufflation systems that heat and humidify carbon dioxide gas while actively sensing intra-abdominal pressure have become standard in laparoscopic and robotic surgery, mitigating post-operative peritoneal hypothermia and pain while preventing sudden loss of pneumoperitoneum during vigorous suctioning. Simultaneously, integrated smoke evacuation systems are experiencing mandated capital adoption across numerous states due to strict clinical safety legislation protecting surgical personnel from carcinogenic and toxic surgical plume generated during electrosurgery. Advanced electrosurgical and ultrasonic energy platforms provide simultaneous vessel sealing and tissue transection, allowing surgical teams to achieve rapid hemostasis without relying on manual suture ligation.
Endotherapy Instrumentation and Accessories
Endotherapy instrumentation and accessories accounted for USD 2.16 billion in 2026, expanding from historical figures of USD 1.71 billion in 2023, USD 1.84 billion in 2024, and USD 1.99 billion in 2025. By 2032, the category is projected to reach USD 3.48 billion, reflecting an 8.27% CAGR from 2027 to 2032. Products encompass an extensive array of high-volume procedural consumables, including biopsy forceps, polypectomy snares, endoscopic hemoclips, foreign body retrieval baskets, balloon dilators, biliary and enteral stents, guide wires, and endoscopic suturing devices.
This category provides medical device manufacturers with an exceptional, high-margin recurring consumable revenue stream that buffers against capital equipment budget cyclicality. As therapeutic endoluminal procedures expand in clinical complexity, the consumption of single-use procedural accessories increases exponentially. Procedures such as endoscopic mucosal resection and endoscopic submucosal dissection require specialized rotational electrosurgical knives, submucosal injection solutions, and automated reloadable hemostatic clip systems to prevent delayed post-procedural hemorrhaging. The ongoing clinical shift toward non-surgical management of complex gastrointestinal bleeding, biliary strictures, and benign mucosal polyps ensures continuous, high-volume procedural demand across community hospitals, tertiary centers, and ambulatory surgery suites.
Reprocessing and Infection Prevention Systems
Reprocessing and infection prevention systems represented USD 1.48 billion in 2026, following historical revenues of USD 1.17 billion in 2023, USD 1.27 billion in 2024, and USD 1.37 billion in 2025. The segment is projected to reach USD 2.34 billion by 2032, demonstrating a 7.93% CAGR from 2027 to 2032. This segment comprises pass-through automated endoscope reprocessors, low-temperature hydrogen peroxide gas plasma sterilizers, automated channel drying and storage cabinets, leak detection systems, and specialized enzymatic cleaning chemistries.
The continuous capital investment in reprocessing systems is propelled by rigorous clinical infection control mandates, extensive FDA post-market surveillance guidelines, and the nationwide adoption of ANSI/AAMI ST91:2021 standards. Health systems must ensure that complex reusable flexible scopes with intricate internal lumina are thoroughly decontaminated, high-level disinfected or sterilized, and protected from microbial recontamination during storage. Modern pass-through automated endoscope reprocessors physically separate contaminated dirty utility areas from clean assembly suites, utilizing radio-frequency identification tags to track individual scope serial numbers, technician handling identities, cycle parameters, and channel fluid dynamics. Automated drying cabinets featuring continuous HEPA-filtered, pressurized air delivery to every internal lumen prevent residual moisture retention, eliminating microbial biofilm proliferation and ensuring scopes remain safe for immediate clinical deployment.
- By Usability and Architecture
The U.S. Endoscopy Devices Market by usability and architecture is segmented into Reusable Endoscopy Systems, Single-Use and Disposable Endoscopes, and Hybrid Endoscopy Platforms.
Reusable Endoscopy Systems
Reusable endoscopy systems represent the foundation of surgical and procedural fleets, accounting for USD 11.45 billion in 2026, up from historical values of USD 9.45 billion in 2023, USD 10.07 billion in 2024, and USD 10.74 billion in 2025. The segment is projected to reach USD 16.89 billion by 2032, advancing at a 6.69% CAGR from 2027 to 2032. This segment comprises traditional, fully sterilizable and reprocessable rigid laparoscopes, arthroscopes, and premium flexible gastrointestinal endoscopes.
The enduring commercial and clinical dominance of reusable endoscopy platforms is anchored in their superior mechanical tactile feedback, extensive operational lifespan, advanced multi-specialty optical customization, and lower per-procedure costs over multi-year high-volume deployments. Rigid laparoscopes and arthroscopes utilized in standard operating rooms are engineered from durable medical-grade stainless steel and sapphire crystal lenses capable of withstanding hundreds of high-pressure autoclave sterilization cycles. In high-volume screening colonoscopy suites, where a single reusable colonoscope may be deployed for several thousand procedures across its operating lifecycle, the amortized capital equipment cost per intervention remains lower than current single-use alternatives. Manufacturers continue to reinforce their reusable installed base by offering multi-year comprehensive service contracts, rapid exchange programs, and modular component upgrades that protect hospital capital investments.
Single-Use and Disposable Endoscopes
Single-use and disposable endoscopes accounted for USD 3.56 billion in 2026, having grown rapidly from USD 2.36 billion in 2023, USD 2.71 billion in 2024, and USD 3.10 billion in 2025. By 2032, the category is projected to reach USD 7.38 billion, exhibiting an extraordinary 12.92% CAGR from 2027 to 2032. This high-growth category encompasses sterile, single-patient-use flexible bronchoscopes, rhinolaryngoscopes, ureteroscopes, cystoscopes, and duodenoscopes.
The unprecedented expansion of single-use endoscopy is driven by infection control mandates, operational workflow simplification, and the complete elimination of sterile processing overhead. In clinical settings characterized by erratic, emergency procedural demands—such as intensive care units, emergency trauma bays, and operating room airway management suites—maintaining dedicated reusable bronchoscopy reprocessors and on-call sterile processing staff is economically inefficient. Single-use bronchoscopes and intubation scopes arrive sterile in individual blister packs, ready for immediate use, and are discarded after procedure completion, eliminating contamination liabilities and equipment turnaround delays. Furthermore, in specialized urology applications, single-use digital ureteroscopes have captured substantial market share by eliminating the frequent, expensive scope repairs historically caused by laser fiber deflection damage in fragile reusable ureteroscopes, providing surgical teams with consistent optical resolution and mechanical deflection for every clinical case.
Hybrid Endoscopy Platforms
Hybrid endoscopy platforms generated USD 1.63 billion in 2026, expanding from historical figures of USD 1.31 billion in 2023, USD 1.40 billion in 2024, and USD 1.51 billion in 2025. The category is on track to achieve USD 2.58 billion by 2032, reflecting a 7.95% CAGR from 2027 to 2032. Hybrid systems combine permanent, high-tier reusable scope insertion shafts, imaging optics, and control bodies with sterile, single-use detachable components, including disposable distal elevator caps, single-use working channels, or disposable instrument sleeves.
This architectural middle-ground addresses the specific infection vulnerabilities of complex interventional scopes without forfeiting the advanced imaging and mechanical handling advantages of high-tier capital equipment. In interventional duodenoscopy, the microscopic crevices beneath the elevator lever represent the single most common failure site during manual cleaning and high-level disinfection. Hybrid duodenoscopes feature a permanent optic body paired with a single-use sterile elevator cap that is clicked into position prior to the procedure and discarded immediately afterward. This configuration enables sterile processing technicians to directly brush and flush all exposed surfaces of the permanent distal tip while guaranteeing a brand-new, sterile mechanical elevator mechanism for every patient. Hybrid models appeal strongly to healthcare systems seeking to satisfy rigorous safety guidelines while amortizing capital costs across large patient volumes.
- By Application
The U.S. Endoscopy Devices Market by application is segmented into Gastrointestinal Endoscopy, Laparoscopy and General Surgery, Arthroscopy and Orthopedic Surgery, Urology Endoscopy, Pulmonology and Bronchoscopy, Gynecology and Obstetrics Endoscopy, and ENT and Neuroendoscopy.
Gastrointestinal Endoscopy
Gastrointestinal endoscopy represents the single largest clinical application, accounting for USD 5.98 billion in 2026, up from USD 4.72 billion in 2023, USD 5.10 billion in 2024, and USD 5.52 billion in 2025. The segment is projected to reach USD 9.48 billion by 2032, advancing at a 7.98% CAGR from 2027 to 2032. Clinical procedures include screening and diagnostic colonoscopies, esophagogastroduodenoscopies, endoscopic retrograde cholangiopancreatography, endoscopic ultrasound, enteroscopies, and endoluminal therapeutic resections.
The sheer procedural volume of colorectal cancer screening constitutes the backbone of this segment. With approximately 15 million screening and surveillance colonoscopies performed annually in the United States, gastrointestinal endoscopy suites generate continuous capital renewal cycles and massive accessory consumption. The clinical integration of artificial intelligence-based polyp detection modules, high-magnification optical chromoendoscopy, and multi-light LED video processors has elevated diagnostic standards, enabling endoscopists to visualize flat, sessile serrated adenomas with superior accuracy. Simultaneously, interventional therapeutic procedures—such as endoscopic submucosal dissection for early-stage mucosal neoplasia and lumen-apposing metal stent placements for pancreatic fluid collections—have expanded the scope of gastrointestinal medicine, turning complex surgical conditions into minimally invasive outpatient interventions.
Laparoscopy and General Surgery
Laparoscopy and general surgery accounted for USD 4.33 billion in 2026, following historical levels of USD 3.41 billion in 2023, USD 3.69 billion in 2024, and USD 3.99 billion in 2025. This segment is projected to achieve USD 6.95 billion by 2032, expanding at an 8.21% CAGR from 2027 to 2032. Procedures encompass laparoscopic cholecystectomies, appendectomies, bariatric gastric bypass and sleeve gastrectomies, ventral and inguinal hernia repairs, colectomies, and anti-reflux fundoplications.
Laparoscopy represents the surgical standard of care across American hospital operating rooms and ambulatory surgical suites. Demand is propelled by the continuous transition from open abdominal surgery to multi-port and single-incision minimally invasive approaches. Equipment utilization is centered on high-definition and 4K rigid laparoscopes, intelligent carbon dioxide insufflators, multi-articulating laparoscopic instruments, trocars, and advanced energy vessel-sealing platforms. Surgeons increasingly demand integrated near-infrared fluorescence imaging capabilities to evaluate real-time tissue perfusion and visually identify biliary ducts via indocyanine green illumination, substantially decreasing intraoperative complications and conversion rates to open surgery.
Arthroscopy and Orthopedic Surgery
Arthroscopy and orthopedic surgery generated USD 2.33 billion in 2026, rising from historical figures of USD 1.84 billion in 2023, USD 1.98 billion in 2024, and USD 2.15 billion in 2025. The category is on track to achieve USD 3.69 billion by 2032, exhibiting a 7.96% CAGR from 2027 to 2032. Common clinical indications include knee meniscus repair and anterior cruciate ligament reconstruction, shoulder rotator cuff and labral repairs, hip femoroacetabular impingement resections, and small-joint wrist and ankle debridements.
The steady expansion of orthopedic arthroscopy is sustained by an active aging population seeking to preserve joint mobility, alongside high athletic sports injury rates among younger demographics. Orthopedic surgeons rely heavily on rigid arthroscopes with varied viewing angles, automated fluid management inflow and outflow pumps that maintain joint distension and clear visualization, and high-frequency radiofrequency ablation wands that debride soft tissue with minimal thermal damage to articular cartilage. A notable innovation within this segment is the clinical adoption of miniaturized needle-arthroscopy systems, which enable minimally invasive diagnostic joint inspections and minor interventions directly within outpatient physician office suites under local anesthesia, bypassing traditional operating room overhead.
Urology Endoscopy
Urology endoscopy accounted for USD 1.67 billion in 2026, expanding from USD 1.31 billion in 2023, USD 1.42 billion in 2024, and USD 1.54 billion in 2025. By 2032, the category is projected to reach USD 2.78 billion, reflecting an 8.86% CAGR from 2027 to 2032. Procedural domains include flexible and rigid cystoscopies, diagnostic and therapeutic ureteroscopies for nephrolithiasis, percutaneous nephrolithotomies, and transurethral resections of the prostate and bladder tumors.
Urological device procurement is propelled by the high national prevalence of kidney stone disease and bladder cancer. Kidney stone interventions have been transformed by single-use digital flexible ureteroscopes paired with high-power holmium and thulium fiber lasers, allowing urologists to navigate tortuous renal calyces and pulverize large staghorn calculi with exceptional precision. The rapid transition toward single-use ureteroscopes has resolved long-standing equipment fragility concerns, as laser fiber strikes frequently damaged expensive reusable scope working channels. In outpatient bladder cancer surveillance, high-definition flexible digital cystoscopes equipped with narrow band imaging and blue-light fluorescence illumination enable early detection of carcinoma in situ, significantly improving longitudinal patient management.
Pulmonology and Bronchoscopy
Pulmonology and bronchoscopy generated USD 1.01 billion in 2026, up from historical levels of USD 0.79 billion in 2023, USD 0.86 billion in 2024, and USD 0.93 billion in 2025. The segment is on track to achieve USD 1.74 billion by 2032, demonstrating a 9.49% CAGR from 2027 to 2032. Applications include diagnostic flexible bronchoscopies, endobronchial ultrasound transbronchial needle aspirations for lung cancer staging, therapeutic airway stenting, foreign body retrievals, and robotic-assisted peripheral lung nodule biopsies.
This segment represents one of the fastest-growing clinical domains within interventional medicine, fueled by the widespread clinical rollout of low-dose computed tomography lung cancer screening programs across the United States. Early detection of asymptomatic peripheral pulmonary nodules has generated massive procedural demand for advanced diagnostic bronchoscopy platforms capable of safely accessing distal lung parenchymal tissue. Robotic-assisted bronchoscopy platforms utilizing continuous shape-sensing catheter navigation have achieved high diagnostic yields while minimizing pneumothorax risks. Simultaneously, single-use flexible bronchoscopes have become an indispensable clinical standard across hospital intensive care units and emergency departments, where they are routinely deployed for bedside bronchoalveolar lavage, airway secretion clearance, and difficult endotracheal intubations.
Gynecology and Obstetrics Endoscopy
Gynecology and obstetrics endoscopy accounted for USD 0.82 billion in 2026, having grown from USD 0.65 billion in 2023, USD 0.70 billion in 2024, and USD 0.76 billion in 2025. The category is projected to reach USD 1.38 billion by 2032, exhibiting a 9.06% CAGR from 2027 to 2032. Clinical procedures include diagnostic and operative hysteroscopies for abnormal uterine bleeding, uterine fibroid and polyp resections, laparoscopic hysterectomies, myomectomies, and surgical excisions of complex endometriosis.
The expansion of gynecological endoscopy is heavily supported by updated clinical practice guidelines from the American College of Obstetricians and Gynecologists, which emphasize uterine-preserving, minimally invasive alternatives to open abdominal surgery. Operative hysteroscopy has experienced rapid clinical migration from hospital operating rooms to outpatient physician office environments, enabled by compact, all-in-one fluid management carts and single-use mechanical tissue resection systems that morcellate and aspirate intra-uterine pathology without thermal energy. In surgical laparoscopy, high-definition 3D visualization and advanced bipolar vessel sealers enable gynecologists to perform complex laparoscopic hysterectomies and deep infiltrating endometriosis resections through tiny incisions, drastically shortening patient recovery intervals.
ENT and Neuroendoscopy
ENT and neuroendoscopy generated USD 0.50 billion in 2026, following historical figures of USD 0.40 billion in 2023, USD 0.43 billion in 2024, and USD 0.46 billion in 2025. The category is projected to reach USD 0.83 billion by 2032, expanding at an 8.81% CAGR from 2027 to 2032. Procedures encompass functional endoscopic sinus surgery, diagnostic flexible laryngoscopy, skull-base transsphenoidal pituitary tumor resections, endoscopic third ventriculostomies, and minimally invasive spinal microdiscectomies.
Clinical growth across this specialized segment is driven by the micro-surgical need to access delicate, deeply situated anatomical compartments with minimal collateral tissue disruption. In otolaryngology, functional endoscopic sinus surgery relies on rigid wide-angle endoscopes integrated with real-time electromagnetic surgical navigation systems, allowing otolaryngologists to debride diseased ethmoid and frontal sinus mucosa while avoiding vital orbital and intracranial structures. In cranial neurosurgery, high-definition endoscopes are utilized for transsphenoidal access to pituitary adenomas through the nasal cavity, eliminating external craniotomies and accelerating patient recovery. In spine surgery, full-endoscopic lumbar discectomies performed through working-channel endoscopes under continuous fluid irrigation allow surgeons to decompress herniated discs under direct visualization, preserving paraspinal musculature and stabilizing spinal mechanics.
- By Technology and Modality
The U.S. Endoscopy Devices Market by technology and modality is segmented into High-Definition and 4K UHD Systems, 3D and Artificial Intelligence-Powered Endoscopy Systems, Narrow Band and Advanced Optical Imaging Modalities, Capsule Endoscopy Systems, and Robotically-Assisted Endoscopy Systems.
High-Definition and 4K UHD Systems
High-definition and 4K UHD systems represent the largest technology segment, accounting for USD 6.99 billion in 2026, following historical levels of USD 5.51 billion in 2023, USD 5.96 billion in 2024, and USD 6.45 billion in 2025. The category is projected to reach USD 10.98 billion by 2032, advancing at a 7.82% CAGR from 2027 to 2032. This technology category includes medical-grade 4K camera processors, chip-on-tip high-definition endoscopes, 4K multi-modality surgical displays, and ultra-high-definition optical zoom couplers.
The primacy of 4K ultra-high-definition imaging lies in its unmatched spatial resolution, color contrast depth, and electronic zoom capabilities. By delivering four times the pixel density of legacy 1080p high-definition monitors, 4K systems allow surgeons and endoscopists to view microscopic tissue textures and subtle vascular patterns from greater working distances without pixelation. Modern 4K visualization platforms incorporate high dynamic range color processing that captures deep blacks and bright highlights simultaneously, eliminating overexposed glare from metallic surgical instruments and underexposed shadow areas within deep anatomical cavities. Healthcare facilities prioritize 4K capital fleet standardizations because these versatile consoles support multi-specialty workflows spanning general surgery, gastroenterology, arthroscopy, and urology, optimizing institutional capital expenditures.
3D and Artificial Intelligence-Powered Endoscopy Systems
3D and artificial intelligence-powered endoscopy systems accounted for USD 3.38 billion in 2026, up from USD 2.62 billion in 2023, USD 2.85 billion in 2024, and USD 3.10 billion in 2025. The segment is projected to achieve USD 5.76 billion by 2032, expanding at a 9.29% CAGR from 2027 to 2032. Products include computer-aided detection and diagnosis software consoles, 3D stereoscopic laparoscopic camera systems, polarimetric 3D displays, and passive polarized surgical eyewear.
This technology classification represents one of the most clinically impactful frontiers in modern interventional medicine. Stereoscopic 3D laparoscopy restores natural binocular depth perception and spatial orientation that are inherently lost on traditional flat 2D monitors, allowing surgeons to execute complex intracorporeal suturing, knot-tying, and precise tissue dissection with reduced cognitive fatigue and fewer technical errors. Simultaneously, edge artificial intelligence processing modules analyze live endoscopic video in real time, detecting colorectal adenomas, measuring lesion sizes, and evaluating mucosal microvascular patterns. By standardizing diagnostic accuracy across variable operator experience levels, AI-assisted endoscopy systems assist healthcare systems in meeting clinical quality benchmarks and reducing malpractice liabilities associated with missed colorectal malignancies.
Narrow Band and Advanced Optical Imaging Modalities
Narrow band and advanced optical imaging modalities accounted for USD 2.94 billion in 2026, having grown from USD 2.36 billion in 2023, USD 2.54 billion in 2024, and USD 2.73 billion in 2025. By 2032, the segment is projected to reach USD 4.47 billion, reflecting a 7.23% CAGR from 2027 to 2032. This group encompasses narrow band imaging, linked color imaging, blue light imaging, flexible spectral imaging color enhancement, and indocyanine green near-infrared fluorescence visualization.
The commercial and clinical value of advanced optical chromoendoscopy stems from its ability to enhance mucosal surface architecture and microvascular patterns without introducing external chemical dyes. By filtering white light into discrete, narrow spectral bands corresponding to the hemoglobin absorption spectrum, these platforms dramatically increase the optical contrast between normal mucosal tissue and neoplastic microvasculature. In upper gastrointestinal surveillance, optical chromoendoscopy facilitates targeted biopsies of subtle dysplastic islands in Barrett’s esophagus, eliminating the need for random, multi-quadrant blind tissue sampling. In surgical laparoscopy, indocyanine green fluorescence imaging enables real-time visual verification of vascular perfusion prior to bowel anastomoses, substantially lowering the incidence of catastrophic post-operative anastomotic leaks.
Capsule Endoscopy Systems
Capsule endoscopy systems accounted for USD 1.45 billion in 2026, following historical figures of USD 1.18 billion in 2023, USD 1.26 billion in 2024, and USD 1.35 billion in 2025. The category is projected to reach USD 2.18 billion by 2032, exhibiting a 7.03% CAGR from 2027 to 2032. Products include ingestible diagnostic video capsules, wearable external sensor belts and data recorders, proprietary workstation software suites, and cloud-based AI reading platforms.
Capsule endoscopy provides a patient-friendly, non-invasive diagnostic modality designed to visualize luminal compartments that are inaccessible via conventional upper gastroscopy and lower colonoscopy, particularly the entire length of the small intestine. Key clinical indications include obscure gastrointestinal bleeding, suspected Crohn’s disease, celiac disease monitoring, and small-bowel polyposis syndromes. The integration of machine learning algorithms into review workstation software has shortened clinical interpretation times, as automated AI software filters out thousands of repetitive, uninformative frames and highlights frames containing active bleeding, angiodysplasias, or mucosal ulcerations. Ongoing engineering advances focus on magnetically steered capsules, expanded battery lifespans, 360-degree panoramic imaging angles, and disposable colon capsules for non-invasive colorectal cancer screening in patients unwilling or unable to undergo standard colonoscopy.
Robotically-Assisted Endoscopy Systems
Robotically-assisted endoscopy systems generated USD 1.88 billion in 2026, expanding from USD 1.45 billion in 2023, USD 1.57 billion in 2024, and USD 1.72 billion in 2025. The segment is on track to achieve USD 3.46 billion by 2032, reflecting a 10.70% CAGR from 2027 to 2032. This technologically sophisticated segment comprises robotic endoluminal navigation consoles, shape-sensing flexible robotic catheter systems, motorized robotic endoscope positioners, and natural orifice transluminal robotic surgical platforms.
Robotic endoscopy represents the fastest-growing technology segment in the market, driven by the demand for sub-millimeter anatomical precision, tremor elimination, and stable peripheral catheter anchoring during complex interventional procedures. In pulmonology, robotic bronchoscopy platforms have established a new standard of care for peripheral pulmonary nodule biopsy, allowing interventionalists to navigate deep into the lung periphery and obtain diagnostic tissue samples from lesions under 15 millimeters in diameter. In gastrointestinal surgery, emerging robotic platforms feature articulating multi-jointed micro-instruments that pass through flexible endoscopic working channels, providing surgeons with bimanual dexterity and counter-traction inside the gastrointestinal lumen to perform full-thickness resections and complex defect closures through natural orifices.
- By End User
The U.S. Endoscopy Devices Market by end user is segmented into Hospitals and Tertiary Academic Medical Centers, Ambulatory Surgery Centers, Specialized Outpatient Endoscopy Clinics and Physician Suites, and Diagnostic Imaging and Specialty Treatment Centers.
Hospitals and Tertiary Academic Medical Centers
Hospitals and tertiary academic medical centers represent the largest end-user category, accounting for USD 10.15 billion in 2026, up from USD 8.39 billion in 2023, USD 8.93 billion in 2024, and USD 9.52 billion in 2025. The segment is projected to reach USD 15.57 billion by 2032, expanding at a 7.39% CAGR from 2027 to 2032. This institutional segment comprises large integrated delivery networks, community acute care hospitals, children’s hospitals, and prestigious university teaching institutions.
Tertiary medical centers represent the premier customers for capital-intensive, cutting-edge endoscopy technologies due to their high patient acuity, complex surgical caseloads, and multi-disciplinary academic programs. These institutions maintain extensive inventories of specialized capital hardware, including 4K visualization towers, indocyanine green fluorescence systems, multi-slice endoscopic ultrasound consoles, robotic bronchoscopy platforms, and comprehensive automated endoscope reprocessing departments. Hospitals handle high-risk inpatient surgical procedures, acute gastrointestinal hemorrhages, severe polytrauma, and complex oncological resections that require around-the-clock procedural readiness. Furthermore, academic teaching hospitals act as vital proving grounds for emerging technologies, partnering with medical device manufacturers to conduct pivotal clinical trials that validate the safety and diagnostic efficacy of next-generation endoluminal platforms.
Ambulatory Surgery Centers
Ambulatory surgery centers accounted for USD 4.24 billion in 2026, having grown rapidly from USD 3.02 billion in 2023, USD 3.37 billion in 2024, and USD 3.78 billion in 2025. By 2032, the category is projected to reach USD 7.65 billion, demonstrating an exceptional 10.34% CAGR from 2027 to 2032. This high-growth segment encompasses independent and corporate-affiliated outpatient surgical facilities specializing in same-day surgical and procedural interventions.
The rapid growth of ambulatory surgery centers reflects the nationwide structural migration of elective minimally invasive procedures out of expensive inpatient hospital environments. Ambulatory surgery centers offer high operational efficiency, streamlined patient check-in workflows, lower out-of-pocket costs for patients, and rapid operating room turnover times that allow physicians to perform more procedures per day. In response to favorable CMS outpatient reimbursement schedules, ambulatory facilities are investing heavily in dedicated laparoscopic towers, high-definition arthroscopy suites, flexible colonoscopes, and single-use digital ureteroscopes. Procurement directors in ambulatory surgery centers prioritize versatile capital equipment with low maintenance requirements, space-saving footprints, intuitive technician interfaces, and high reliability that supports continuous, high-throughput daily procedural schedules.
Specialized Outpatient Endoscopy Clinics and Physician Suites
Specialized outpatient endoscopy clinics and physician suites generated USD 1.56 billion in 2026, expanding from historical revenues of USD 1.18 billion in 2023, USD 1.30 billion in 2024, and USD 1.42 billion in 2025. The segment is on track to achieve USD 2.49 billion by 2032, reflecting an 8.11% CAGR from 2027 to 2032. Facilities in this category include private gastroenterology clinics, urology practices, otolaryngology suites, and independent screening endoscopy centers.
These specialized outpatient clinics focus primarily on high-volume, standardized diagnostic procedures, including screening colonoscopies, upper gastrointestinal endoscopies, flexible cystoscopies, and diagnostic laryngoscopies. Operating outside the complex infrastructure of multi-specialty surgical centers, these practices prioritize cost-effective capital investments that deliver rapid return on investment through direct procedural billings. Essential equipment acquisitions include compact video processors, high-durability flexible endoscopes, tabletop automated endoscope reprocessors, and specialized procedural consumables. Practice owners frequently utilize group purchasing organizations and equipment leasing arrangements to acquire advanced imaging capabilities, such as artificial intelligence-assisted polyp detection modules, to attract patients and maintain high diagnostic quality standards.
Diagnostic Imaging and Specialty Treatment Centers
Diagnostic imaging and specialty treatment centers accounted for USD 0.69 billion in 2026, following historical figures of USD 0.53 billion in 2023, USD 0.58 billion in 2024, and USD 0.63 billion in 2025. The category is projected to reach USD 1.14 billion by 2032, growing at an 8.73% CAGR from 2027 to 2032. This category comprises dedicated outpatient cancer screening centers, interventional radiology facilities, and comprehensive multi-modality diagnostic pavilions.
Procurement within these specialty centers is centered on advanced diagnostic modalities, including capsule endoscopy workstation suites, high-resolution endobronchial ultrasound systems, and specialized interventional access platforms. These centers play an essential role in early cancer detection and non-invasive staging, providing referring physicians with comprehensive diagnostic reports that integrate endoscopic findings with cross-sectional imaging data. Investment in this segment is driven by the growing clinical adoption of capsule endoscopy for longitudinal monitoring of small-bowel diseases and the expansion of outpatient interventional oncology procedures that utilize endoscopic visualization for targeted therapeutic delivery.
Regional Insights: Where the Market is Growing Fastest
The U.S. Endoscopy Devices Market is geographically segmented into four primary commercial regions: the South, the West, the Midwest, and the Northeast. Regional market performance is governed by underlying structural dynamics, including demographic population density, senior citizen concentrations, healthcare system consolidation, certificate-of-need regulatory frameworks, ambulatory surgery center proliferation, state-level infection control mandates, and the geographic distribution of major academic medical centers.
South
The South represents the largest overall commercial regional market for endoscopy devices in the United States, generating USD 5.82 billion in 2026, up from historical levels of USD 4.59 billion in 2023, USD 4.96 billion in 2024, and USD 5.37 billion in 2025. The Southern regional market is projected to reach USD 9.56 billion by 2032, expanding at an 8.62% CAGR from 2027 to 2032. The South’s commercial preeminence is underpinned by its substantial population concentration, nation-leading rates of internal population in-migration, an expanding retiree demographic with high Medicare utilization rates, and a high regional prevalence of gastrointestinal malignancies, obesity, metabolic disease, and chronic cardiopulmonary disorders. Furthermore, widespread healthcare infrastructure modernization and extensive corporate hospital consolidation have accelerated capital equipment acquisition across public, private, and academic medical centers.
Texas represents the dominant economic engine within the Southern endoscopy devices landscape, supported by an expanding population exceeding 31 million residents, massive healthcare delivery networks, and favorable commercial regulatory environments. Major metropolitan regions—including Houston, the Dallas-Fort Worth metroplex, Austin, and San Antonio—host some of the largest medical centers and ambulatory healthcare clusters in the world. The Texas Medical Center in Houston, anchored by institutions such as MD Anderson Cancer Center, Houston Methodist Hospital, and Memorial Hermann Health System, represents an exceptional consumer of cutting-edge endoscopic technology, executing high volumes of complex interventional oncological procedures, robotic bronchoscopies, and advanced laparoscopic resections. Throughout the Dallas-Fort Worth corridor, aggressive expansion of physician-owned ambulatory surgery centers and specialized endoscopy facilities has driven extensive procurement of 4K surgical towers, compact automated endoscope reprocessors, and single-use digital ureteroscopes to manage high regional caseloads of nephrolithiasis and elective orthopedics. Texas health systems maintain aggressive capital replacement schedules, modernizing flexible endoscope fleets to meet high outpatient demand.
Florida represents the second-largest state market within the South, distinguished by its massive senior population, high concentration of Medicare beneficiaries, and substantial seasonal population influxes. Metros such as Miami-Fort Lauderdale, Tampa-St. Petersburg, Orlando, and Jacksonville exhibit dense concentrations of acute care hospitals, large retirement community healthcare centers, and high-throughput ambulatory surgery networks. With over 21% of its population aged 65 and older, Florida experiences extraordinary clinical demand for screening colonoscopies, interventional biliary procedures, and urological endoscopic interventions for benign prostatic hyperplasia and bladder cancer. The state’s healthcare landscape is characterized by high private equity investment into specialized gastroenterology and ophthalmology-urology management platforms, which execute consolidated, multi-facility procurement agreements for standardized endoscopy towers, AI-assisted colonoscopy modules, and recurring procedural accessories. Prominent medical institutions, including the Mayo Clinic in Jacksonville, AdventHealth Orlando, and the University of Miami Health System, serve as regional centers of excellence, driving early adoption of indocyanine green fluorescence imaging and robotic endoluminal navigation systems.
North Carolina and Georgia represent rapidly expanding healthcare technology and clinical service hubs fueled by strong suburban growth, prominent corporate research centers, and elite university medical systems. In North Carolina, the Research Triangle region—encompassing Raleigh, Durham, and Chapel Hill—alongside the Charlotte metropolitan area, supports highly sophisticated academic and private health systems, including Duke University Health System, UNC Health, and Atrium Health. These institutions demonstrate aggressive capital adoption of advanced chip-on-tip visualization systems, robotic pulmonology platforms, and hybrid duodenoscopes. Georgia, anchored by the expanding Atlanta metropolitan area and leading healthcare networks such as Emory Healthcare, Piedmont Healthcare, and Wellstar Health System, exhibits substantial capital deployment across direct digital visualization suites, 4K laparoscopy towers, and enterprise-wide endoscope reprocessing departments designed to satisfy stringent sterile processing compliance standards.
Tennessee, Virginia, and the broader Gulf Coast states—including Louisiana, Alabama, and Mississippi—provide sustained demand across public, private, and rural healthcare delivery systems. Tennessee occupies a unique position as a national nexus for healthcare management, hosting corporate headquarters for major hospital operators such as HCA Healthcare in Nashville, alongside Vanderbilt University Medical Center. Corporate hospital executives in Nashville oversee centralized procurement policies governing hundreds of acute care hospitals and surgery centers across the United States, driving enterprise-level vendor contracts for standardized endoscopic hardware and automated reprocessing platforms. Virginia features an affluent, high-density healthcare corridor across Northern Virginia and Richmond, anchored by Inova Health System and VCU Health, where clinical demand centers on advanced interventional endotherapy and outpatient surgical laparoscopy. In rural expanses across Alabama, Mississippi, and Louisiana, community hospitals and regional health clinics prioritize highly durable, multi-purpose endoscopic visualization systems that deliver dependable service with minimal maintenance requirements.
The commercial dynamics of the South are defined by substantial disparities between well-capitalized, corporate-owned metropolitan hospital networks and resource-constrained rural community facilities. While major urban medical centers rapidly procure robotic endoscopy platforms, single-use duodenoscopes, and AI-enabled screening software, rural facilities focus on cost-effective reusable equipment bundles supported by dependable distributor maintenance networks. Manufacturers that offer flexible equipment financing, cost-per-procedure leasing programs, and dedicated regional clinical training specialists achieve decisive competitive advantages across this expansive geographic territory.
West
The West represents the fastest-growing regional market for endoscopy devices through 2032, accounting for USD 4.33 billion in 2026, following historical revenues of USD 3.41 billion in 2023, USD 3.69 billion in 2024, and USD 3.99 billion in 2025. The Western regional market is projected to reach USD 7.25 billion by 2032, demonstrating a nation-leading 8.97% CAGR from 2027 to 2032. The region’s rapid expansion is propelled by early clinical adoption of emerging technologies, progressive healthcare policy, high penetration of private health insurance, strong presence of integrated managed care systems, and strict environmental and workplace safety regulations that accelerate transitions toward eco-friendly, low-power, and single-use endoscopic platforms.
California represents the undisputed commercial anchor of the Western region and the largest single state market for endoscopy devices in the United States. Supported by a population exceeding 39 million individuals, California is characterized by cutting-edge clinical innovation, concentrated healthcare system leadership, and high healthcare expenditures. The Greater Los Angeles basin, the San Francisco Bay Area, Orange County, and San Diego host premier academic medical systems, including UCLA Health, Stanford Health Care, UCSF Health, Cedars-Sinai Medical Center, and UC San Diego Health. California hospitals operate as the primary national proving grounds for novel endoscopic technologies, driving early clinical trials and commercial procurement of 3D 4K laparoscopic platforms, robotic endoluminal surgical systems, AI-powered computer-aided diagnostic software, and single-use flexible bronchoscopes. Furthermore, massive integrated health networks, led by Kaiser Permanente and Sutter Health, implement standardized, system-wide procurement guidelines that emphasize clinical infection prevention, procedural workflow efficiency, and automated electronic health record integration, compelling medical device vendors to deliver interconnected, software-enabled clinical suites.
Washington and Oregon represent mature, progressive healthcare markets characterized by high health system integration, strong public health infrastructure, and early adoption of evidence-based clinical protocols. The Seattle metropolitan area, anchored by the University of Washington Medicine, Fred Hutchinson Cancer Center, and Providence Health, represents an advanced hub for interventional pulmonology, gastrointestinal oncology, and outpatient surgical innovation. Healthcare systems across the Pacific Northwest demonstrate high institutional commitment to infection prevention and environmental sustainability, actively transitioning from chemical-intensive reprocessing workflows to validated single-use scopes or low-temperature gas plasma sterilization systems. In Oregon, major healthcare networks centered in Portland, including OHSU Healthcare and Legacy Health, drive consistent procurement of digital flexible cystoscopes, advanced laparoscopic energy devices, and outpatient hysteroscopy systems that reduce surgical invasiveness and shorten patient recovery times.
Colorado, Arizona, and Utah represent high-velocity, dynamic interior Western markets fueled by substantial population influxes, expanding technology sectors, and an active demographic prone to orthopedic sports injuries. Colorado’s Front Range corridor, stretching from Fort Collins through Denver to Colorado Springs, represents a major national center for orthopedic surgery, sports medicine, and minimally invasive general surgery. Healthcare systems throughout Colorado, including UCHealth and Centura Health, invest heavily in 4K arthroscopy towers, high-definition visualization systems, and advanced electrosurgical ablation tools to manage high caseloads of knee, shoulder, and hip arthroscopic reconstructions resulting from athletic outdoor activities. Arizona, anchored by Phoenix, Scottsdale, and Tucson, features an expanding year-round healthcare market with high demand for screening colonoscopy fleets, urological stone management equipment, and outpatient endoscopy suites servicing an expanding retiree demographic. Utah, centered on Salt Lake City and the Intermountain Healthcare network, serves as a national benchmark for healthcare operational efficiency and evidence-based equipment utilization, prioritizing multi-functional endoscopy towers that maximize clinical productivity while reducing procedural overhead.
The commercial landscape across the West is characterized by high clinical receptivity to software-as-a-service models, cloud-integrated image management, and stringent hospital infection control protocols. California’s state health department and Cal/OSHA workplace safety mandates have accelerated the adoption of automated smoke evacuation systems in laparoscopic operating rooms and strict sterile processing tracking systems. Equipment vendors that emphasize digital workflow connectivity, enterprise PACS compatibility, comprehensive ergonomics, and documented reductions in hospital-acquired infections capture decisive competitive market shares across Western healthcare networks.
Midwest
The Midwest represents a mature, highly resilient commercial endoscopy devices market, generating USD 3.66 billion in 2026, up from historical levels of USD 2.89 billion in 2023, USD 3.12 billion in 2024, and USD 3.38 billion in 2025. The Midwestern market is projected to reach USD 5.69 billion by 2032, expanding at a 7.63% CAGR from 2027 to 2032. The region’s market is characterized by a balance between massive, world-renowned academic medical centers and large multi-hospital community health systems delivering high-volume surgical and diagnostic services across both major metropolitan areas and rural heartland communities.
Illinois and Ohio represent the primary revenue-generating states within the Midwest, possessing dense concentrations of tertiary medical institutions, major surgical training centers, and expanding outpatient surgery networks. In Illinois, the Chicago metropolitan area encompasses one of the most lucrative healthcare markets in the nation, featuring prominent academic networks such as Northwestern Medicine, University of Chicago Medicine, and Rush University Medical Center. Chicago medical institutions maintain high capital spending on cutting-edge endoscopic platforms, including 4K indocyanine green fluorescence towers, advanced therapeutic gastrointestinal endoscopes, and robotic-assisted bronchoscopy suites. Ohio features an exceptionally strong clinical infrastructure anchored by the Cleveland Clinic, a global leader in clinical innovation and surgical excellence, alongside The Ohio State University Wexner Medical Center in Columbus and TriHealth in Cincinnati. The Cleveland Clinic serves as a primary national clinical evaluation center for emerging minimally invasive technologies, establishing national benchmarks for surgical laparoscopy, bariatric endoscopy, and urological interventions that heavily influence hospital purchasing committees nationwide.
Michigan, Indiana, and Wisconsin provide substantial market demand spanning urban tertiary hospital centers, suburban ambulatory surgery networks, and regional community health systems. Michigan’s healthcare market, centered on Detroit, Ann Arbor, and Grand Rapids, is anchored by leading institutions such as Michigan Medicine, Henry Ford Health, and Corewell Health. These systems exhibit high procurement rates of direct digital visualization consoles, automated endoscope reprocessors, and single-use bronchoscopes deployed across large intensive care unit fleets. Indiana features prominent corporate medical research centers and major healthcare systems in Indianapolis, including IU Health, which serves as a statewide referral hub for complex hepatobiliary endotherapy, interventional pulmonology, and advanced surgical oncology. Wisconsin, anchored by major health systems such as Advocate Aurora Health, Froedtert Health, and the University of Wisconsin Health in Madison, exhibits steady capital procurement of 4K surgical towers, orthopedic arthroscopy systems, and automated infection prevention infrastructure designed to optimize operating room throughput.
Minnesota, Iowa, Missouri, and the Plains States—including Kansas, Nebraska, and the Dakotas—represent critical regional clinical referral territories characterized by centralized healthcare delivery and high patient acuity. Minnesota hosts the global headquarters of the Mayo Clinic in Rochester, universally recognized as a pinnacle of clinical research, diagnostic precision, and advanced interventional endoscopy. The Mayo Clinic represents an extraordinary institutional buyer of state-of-the-art medical technology, conducting pioneering work in endoluminal robotic surgery, artificial intelligence-assisted diagnostics, and novel therapeutic endotherapy. Iowa and Missouri, anchored by University of Iowa Hospitals and Clinics in Iowa City, BJC HealthCare in St. Louis, and Saint Luke’s Health System in Kansas City, maintain large-scale clinical programs in gastrointestinal cancer screening, interventional urology, and outpatient minimally invasive surgery that drive steady capital renewal cycles and recurring procedural consumable purchases.
Procurement behavior across the Midwest is defined by disciplined capital budgeting, rigorous clinical value analysis, and a strong institutional preference for total cost of ownership models that demonstrate clear procedural efficiencies and durable equipment lifespans. Hospital value analysis committees across Midwestern health systems carefully scrutinize equipment reliability, warranty terms, and preventive maintenance contract structures. Medical device manufacturers succeed in this region by providing transparent long-term pricing, dependable local service engineering support, comprehensive clinical education for surgical teams, and robust multi-year fleet repair agreements.
Northeast
The Northeast represents a highly sophisticated, high-density commercial market, accounting for USD 2.83 billion in 2026, having grown from USD 2.23 billion in 2023, USD 2.41 billion in 2024, and USD 2.61 billion in 2025. The Northeastern market is projected to reach USD 4.35 billion by 2032, demonstrating a 7.43% CAGR from 2027 to 2032. While the Northeast is geographically more compact than the South or Midwest, it features the nation’s highest geographic concentration of elite academic medical centers, Ivy League teaching hospitals, specialized cancer institutes, and prestigious surgical fellowship training programs.
New York represents the economic cornerstone of the Northeastern endoscopy devices market, driven by the massive concentration of healthcare infrastructure and surgical volume across the New York City metropolitan area, Long Island, and Westchester County, complemented by extensive upstate healthcare networks. New York City hosts world-renowned academic medical institutions, including NewYork-Presbyterian Hospital, Memorial Sloan Kettering Cancer Center, Mount Sinai Health System, and NYU Langone Health. These premier institutions operate with surgical and endoscopic equipment inventories that set global benchmarks for clinical sophistication. Facilities in New York invest heavily in space-saving, ceiling-mounted 4K surgical visualization booms, integrated operating room digital management platforms, advanced therapeutic endotherapy suites, and single-use endoscope fleets to navigate constrained urban hospital real-estate footprints and high daily patient volumes. Upstate New York, anchored by health networks such as the University of Rochester Medical Center and Albany Medical Center, maintains consistent capital procurement across screening colonoscopy fleets, laparoscopic towers, and automated sterile processing equipment.
Pennsylvania represents the second-largest state market within the Northeast, supported by dense clinical populations and prestigious medical institutions across Philadelphia and Pittsburgh. In Philadelphia, health systems including the Hospital of the University of Pennsylvania, Jefferson Health, and Temple Health maintain world-class clinical programs in gastrointestinal interventional endoscopy, advanced laparoscopy, and urology, driving aggressive capital deployment across chip-on-tip visualization consoles, AI-assisted diagnostic modules, and robotic endoluminal platforms. In Pittsburgh, the University of Pittsburgh Medical Center represents a global integrated healthcare delivery giant that executes centralized enterprise procurement across dozens of hospitals and outpatient surgical facilities, demanding standardized equipment platforms, predictable multi-year consumable pricing, and comprehensive clinical staff education programs.
Massachusetts, New Jersey, and Connecticut represent exceptionally affluent, technology-dense healthcare markets characterized by high health insurance coverage, advanced clinical research infrastructure, and high per-capita healthcare spend. The Boston metropolitan area serves as an international epicenter for biomedical research and medical device innovation, anchored by premier teaching hospitals including Massachusetts General Hospital, Brigham and Women’s Hospital, and Beth Israel Deaconess Medical Center. These institutions maintain cutting-edge clinical suites, actively piloting prototype endoscopic hardware, novel optical chromoendoscopy filters, and machine-learning diagnostic algorithms. New Jersey, with its dense pharmaceutical corridor and leading health systems such as Hackensack Meridian Health and RWJBarnabas Health, exhibits heavy capital investment in outpatient ambulatory surgery center suites, high-definition cystoscopy systems, and single-use ureteroscopes. Connecticut, anchored by Yale New Haven Health, demonstrates steady adoption of 4K laparoscopic platforms, robotic bronchoscopy systems, and automated endoscope reprocessors designed to meet stringent state infection prevention protocols.
Maryland, Rhode Island, Maine, New Hampshire, and Vermont complete the Northeastern market landscape, providing consistent commercial demand across academic, suburban, and rural clinical delivery settings. Maryland represents an essential clinical and regulatory anchor, hosting the Johns Hopkins Health System in Baltimore, a premier global center for surgical research and interventional endotherapy, alongside close proximity to the Food and Drug Administration headquarters. Johns Hopkins researchers routinely establish clinical practice parameters that guide national endoscopic device adoption. Across Northern New England, community hospital networks prioritize rugged, dependable visualization systems and cost-effective single-use intubation scopes to maintain continuous clinical readiness across decentralized rural emergency and intensive care facilities.
Procurement throughout the Northeast is heavily evidence-driven, scientifically rigorous, and guided by prominent clinical key opinion leaders. Hospital purchasing decisions are heavily influenced by clinical trial data, peer-reviewed literature, and the recommendations of academic department chairs. Equipment vendors must deliver uncompromising optical engineering, robust electrical safety standards, seamless integration with hospital-wide enterprise networks, and comprehensive technical documentation to succeed in this scientifically exacting regional healthcare market.
Key Market Players
The competitive landscape of the U.S. Endoscopy Devices Market is characterized by a balance between diversified multinational medical technology corporations, specialized minimally invasive surgical equipment manufacturers, and agile innovators pioneering single-use endoscopic platforms.
Highly relevant players operating in the U.S. endoscopy devices industry include:
Olympus Corporation
Stryker Corporation
Boston Scientific Corporation
KARL STORZ SE & Co. KG
Medtronic plc
Johnson & Johnson (Ethicon Endo-Surgery, Inc.)
FUJIFILM Holdings America Corporation
CONMED Corporation
Richard Wolf GmbH
Ambu A/S
Smith & Nephew plc
Cook Medical LLC
STERIS plc
PENTAX Medical (HOYA Group)
Arthrex, Inc.
Olympus Corporation represents the preeminent market leader in flexible gastrointestinal endoscopy, commanding the largest installed base of colonoscopes, gastroscopes, and duodenoscopes across U.S. hospitals and ambulatory surgery centers. Olympus differentiates itself through its flagship EVIS X1 video endoscopy system, which integrates advanced optical diagnostic modalities, including Texture and Color Enhancement Imaging, Red Dichromatic Imaging, and Narrow Band Imaging. The company’s comprehensive portfolio extends across interventional endotherapy devices, high-throughput automated endoscope reprocessors, and surgical visualization platforms. Olympus reinforces its commercial dominance by providing extensive hospital service contracts, rapid-response loaner scope fleets, and long-term capital equipment leasing agreements that secure enterprise customer retention across American healthcare systems.
Stryker Corporation is the recognized market powerhouse in rigid surgical visualization, operating room integration, and sports medicine arthroscopy. Through its Endoscopy division, Stryker provides the 1688 and 1788 Advanced Imaging 4K visualization platforms, which integrate native 4K UHD video processing with advanced fluorescence imaging utilizing indocyanine green for real-time tissue perfusion and intraoperative biliary anatomy mapping. Stryker’s commercial dominance is fortified by its iSuite operating room integration technology, which seamlessly unites ceiling booms, surgical displays, surgical lighting, and wireless device controls into unified surgical suites. Stryker leverages broad cross-specialty hospital supply agreements, bundling surgical endoscopy hardware with orthopedic power tools, patient handling equipment, and surgical instruments to secure multi-year capital standardizations.
Boston Scientific Corporation has established itself as an aggressive category creator and commercial leader in single-use flexible endoscopy and interventional endotherapy consumables. Boston Scientific transformed the urological market with its LithoVue single-use digital flexible ureteroscope and pioneered disposable gastrointestinal endoscopy with the launch of the EXALT Model D single-use duodenoscope for ERCP procedures. The company commands an extensive portfolio of specialized therapeutic endotherapy accessories, including the hot AXIOS lumen-apposing stent, Resolution 360 hemostasis clips, Expect endoscopic ultrasound needles, and SpyGlass DS direct visualization cholangiopancreatoscopy systems. Boston Scientific’s commercial strategy focuses on converting complex surgical procedures into outpatient endoluminal interventions while eliminating device-related infection risks through single-use architectures.
KARL STORZ SE & Co. KG represents the benchmark in German optical precision and rigid surgical instrumentation, maintaining an expansive market footprint through its U.S. subsidiary, KARL STORZ Endoscopy-America. The company’s flagship IMAGE1 S 4K camera platform delivers modular visualization across rigid laparoscopy, arthroscopy, cystoscopy, and otorhinolaryngology, supporting multi-spectral imaging modes such as CLARA, CHROMA, and OPAL1 near-infrared indocyanine green fluorescence. KARL STORZ is renowned for its premium stainless-steel hand instruments, wide-angle Hopkins rod-lens optics, and OR1 operating room integration systems. The company caters to discerning surgical specialists and tertiary academic medical centers that demand unmatched durability, optical resolution, and precision ergonomics across multi-disciplinary surgical suites.
Medtronic plc commands a formidable, diversified presence across minimally invasive surgical visualization, electrosurgical energy, and artificial intelligence-driven gastrointestinal diagnostics. Medtronic transformed colorectal cancer screening through the commercialization of the GI Genius intelligent endoscopy module, an FDA-cleared computer-aided detection system that utilizes deep learning artificial intelligence to highlight pre-cancerous polyps in real time during colonoscopies. Medtronic is also the pioneer of ingestible diagnostic imaging through its PillCam capsule endoscopy platform, which dominates small-bowel mucosal imaging. Medtronic integrates these diagnostic platforms with its Valleylab electrosurgical energy systems and surgical stapling portfolios, enabling the company to bundle capital visualization hardware with high-velocity operating room consumables across major hospital networks.
Johnson & Johnson, through its Ethicon Endo-Surgery subsidiary, represents an essential pillar of the American minimally invasive surgical landscape. While specializing extensively in advanced energy systems and endomechanical surgical devices, Ethicon delivers foundational technologies that enable laparoscopic and endoscopic operative procedures. The company’s HARMONIC ultrasonic cutting devices, ENSEAL advanced bipolar tissue sealers, and ENDOPATH access trocars are ubiquitous across American operating rooms. Ethicon leverages Johnson & Johnson’s massive institutional balance sheet to execute long-term enterprise supply contracts with large integrated delivery networks, securing sole-source procurement agreements for operative accessories, hand instruments, and wound closure systems utilized in minimally invasive surgery.
FUJIFILM Holdings America Corporation is a major technological competitor in flexible gastrointestinal endoscopy, surgical laparoscopy, and optical innovation. Leveraging its historic expertise in photographic physics and digital imaging, Fujifilm delivers the ELUXEO 7000 video endoscopy platform, which utilizes a 4-LED multi-light illumination engine to unlock proprietary Linked Color Imaging and Blue Light Imaging modalities. These advanced spectral technologies enhance subtle mucosal redness and surface patterns to improve early gastric and colorectal lesion detection. Fujifilm has expanded its commercial reach through its double-balloon enteroscopy systems, compact surgical laparoscopy towers, and full-thickness endoscopic resection accessories, providing academic medical centers and specialized endoscopy clinics with high-performance alternatives to traditional market incumbents.
CONMED Corporation is an established U.S. medtech manufacturer specializing in minimally invasive surgical operative equipment, insufflation systems, and orthopedic arthroscopy. CONMED is globally celebrated for its AirSeal intelligent flow insufflation system, a clinically transformative platform that maintains a stable, valveless pneumoperitoneum with continuous smoke evacuation and active pressure sensing during laparoscopic and robotic surgeries. CONMED’s surgical portfolio also features the 500 X-Treme 4K visualization system, Hall surgical powered handpieces, and an extensive catalog of electrosurgical generators and disposable arthroscopic access cannulas. The company’s focus on operating room efficiency and surgical plume safety makes it a favored partner for high-throughput ambulatory surgery centers.
Richard Wolf GmbH maintains a strong presence across U.S. hospitals and academic centers through its American subsidiary, Richard Wolf Medical Instruments Corp. The company specializes in precision German-engineered rigid endoscopic optics, modular camera systems, and specialized interventional suites for urology, laparoscopy, and spine surgery. The company’s ENDOCAM Logic 4K visualization console provides brilliant spatial resolution and integrated special light modes for subtle tissue differentiation. Richard Wolf is a global pioneer in minimally invasive spine endoscopy, providing full-endoscopic lumbar discectomy systems and specialized nephroscopes for percutaneous nephrolithotomy that allow surgeons to navigate delicate spinal and renal compartments under high-magnification fluid immersion.
Ambu A/S represents the undisputed volume pioneer and global leader in single-use flexible endoscopy, maintaining a massive commercial footprint through its U.S. headquarters, Ambu Inc. Ambu disrupted pulmonary medicine with the launch of its aScope flexible single-use bronchoscopy platform, which has become standard equipment across American intensive care units, emergency departments, and operating rooms. The company has aggressively expanded its single-use portfolio into urology with the aScope 4 Cysto, otorhinolaryngology with the aScope 4 RhinoLaryngo, gastrointestinal medicine with the aScope Duodeno, and interventional pulmonology with the aScope 5 Broncho. Ambu’s high-volume automated manufacturing, low cost per unit, and sterile single-patient-use architecture eliminate scope reprocessing burdens and provide immediate procedural readiness across critical care environments.
Smith & Nephew plc is a global leader in orthopedic sports medicine and arthroscopic surgical devices, operating an extensive manufacturing and commercial infrastructure throughout the United States. Smith & Nephew commands substantial market share in joint repair, providing high-definition 4K arthroscopy camera systems, specialized motorized shaver handpieces, and the Werewolf COBLATION technology platform. COBLATION technology utilizes low-temperature radiofrequency energy to precisely ablate and debride articular cartilage and soft tissue while minimizing thermal damage to surrounding healthy tissue. The company’s vast array of meniscal repair systems, suture anchors, and fluid management pumps makes it an essential supplier for orthopedic ambulatory surgery centers nationwide.
Cook Medical LLC is a premier privately held American medical device pioneer commanding a dominant global presence in interventional endotherapy accessories and minimally invasive access systems. Cook Medical’s Endoscopy division delivers specialized consumable instruments that pass through flexible endoscope working channels to diagnose and treat complex hepatobiliary, gastrointestinal, and pulmonary disorders. Flagship product lines include EchoTip Ultra and ProCore endoscopic ultrasound biopsy needles, the Instinct plus endoscopic hemoclip, Evolution biliary and colonic metal stents, and Geenen biliary sphincterotomes. Cook Medical differentiates itself through rigorous physician education programs, high-precision instrument mechanics, and long-standing partnerships with clinical gastroenterologists and interventional pulmonologists.
STERIS plc represents the foundational global benchmark in infection prevention, sterile processing infrastructure, and automated endoscope reprocessing systems. Operating extensive manufacturing and commercial operations across North America, STERIS equips hospital central sterile supply departments and endoscopy processing suites with automated endoscope reprocessors, including the Reliance and System 1E liquid chemical sterilant processing systems. STERIS also manufactures pass-through drying and storage cabinets, automated leak testing equipment, and specialized enzymatic cleaning chemistries. Beyond capital equipment, STERIS delivers endoscopy transport carts, single-use scope tracking valves, and comprehensive equipment repair services, positioning itself as an indispensable partner for healthcare institutions seeking strict compliance with infection control standards.
PENTAX Medical, a division of Japan’s HOYA Group, is a prominent global manufacturer of flexible gastrointestinal and pulmonology endoscopy systems with extensive operations throughout the United States. PENTAX Medical delivers the OPTIVISTA plus and INSPIRA video processor platforms, combining optical and digital chromoendoscopy through proprietary i-scan image processing algorithms to enhance mucosal surfaces and vascular structures. PENTAX Medical addressed the duodenoscope contamination crisis by commercializing the DEC duodenoscope, which features a disposable distal elevator cap that combines the high optical quality of a reusable scope with a sterile single-use elevator mechanism. PENTAX Medical maintains strong commercial presence across hospital endoscopy units and academic medical centers, offering competitive equipment pricing and durable product architectures.
Arthrex, Inc. is an undisputed global titan in orthopedic surgical technology, sports medicine, and minimally invasive joint visualization, operating extensive corporate and manufacturing campuses in Florida. Arthrex manufactures the Synergy 4K imaging platform, a multi-specialty visualization system that integrates 4K camera processing, LED illumination, image capture, and medical tablet data management into a single console. Arthrex is also the pioneer of the NanoScope, a 1.9-millimeter chip-on-tip needle-arthroscopy system that allows orthopedic surgeons to perform minimally invasive diagnostic joint examinations and therapeutic procedures directly in outpatient physician offices under local anesthesia. Supported by an exhaustive catalog of thousands of specialized orthopedic implants, suture anchors, and bioabsorbable fixation devices, Arthrex commands deep brand loyalty among American orthopedic surgeons.
Recent Developments
The U.S. endoscopy devices industry has undergone profound corporate consolidation, technological acceleration, and regulatory transformation since 2024.
A defining structural development has been the aggressive commercial rollout and hospital-wide integration of real-time artificial intelligence algorithms within gastrointestinal endoscopy and surgical visualization. Following the pioneering commercialization of AI-assisted colonoscopy detection systems, major video processor manufacturers have embedded machine learning algorithms directly into hardware consoles. Between late 2024 and 2026, healthcare providers widely adopted computer-aided detection and computer-aided diagnosis software capable of identifying flat sessile adenomas, classifying mucosal pit patterns, and estimating histological polyp types in real time. Clinical trials demonstrating statistically significant increases in adenoma detection rates have compelled hospital value analysis committees to prioritize AI-enabled upgrades to satisfy payer quality reporting metrics and enhance early cancer interception.
The regulatory and clinical accreditation landscape has simultaneously enforced stringent infection prevention mandates that have permanently altered endoscope fleet composition. The widespread clinical adoption of ANSI/AAMI ST91:2021 standards, reinforced by updated safety communications from the U.S. Food and Drug Administration, has established demanding benchmarks for manual cleaning verification, borescope channel inspection, automated reprocessing documentation, and channel drying. Hospitals face significant labor and capital costs to maintain compliance with these multi-step standards. Consequently, medical facilities have rapidly accelerated the procurement of single-use flexible bronchoscopes, cystoscopes, and duodenoscopes. In procedures involving high-risk elevator mechanisms, healthcare systems have systematically phased out fixed-endcap duodenoscopes in favor of hybrid scopes with disposable elevator caps or fully disposable single-use duodenoscopes.
Reimbursement structures established by the Centers for Medicare and Medicaid Services have evolved to support the adoption of infection-resistant endoscopic devices and outpatient procedural migration. CMS expanded New Technology Add-on Payments and transitional pass-through device payment codes (such as C-codes) for single-use duodenoscopes and advanced endotherapy devices utilized within hospital inpatient and outpatient departments. These supplemental payments have partially offset initial product acquisition costs, allowing clinical departments to evaluate single-use scopes without incurring financial deficits. Concurrently, the annual expansion of the CMS Ambulatory Surgical Center Covered Procedures List has enabled outpatient surgery centers to capture expanded procedural volumes in complex spine endoscopy, joint arthroscopy, and gynecological hysteroscopy, reinforcing capital investment in compact 4K towers and single-use instrumentation.
Miniaturization and needle-endoscopy technologies have achieved widespread clinical validation, enabling a new category of office-based minimally invasive procedures. The commercial introduction of ultra-miniaturized chip-on-tip visualization systems with outer diameters under two millimeters has allowed orthopedic surgeons, rheumatologists, and urologists to perform direct diagnostic joint inspections and cystoscopies within outpatient examination rooms under local anesthesia. These needle-visualization systems eliminate the substantial financial overhead, operating room scheduling delays, and general anesthesia risks associated with traditional hospital surgical suites, providing patients with immediate diagnostic confirmation and targeted therapeutic interventions in a single visit.
Surgical visualization has experienced a technological transformation through the convergence of native 4K ultra-high-definition imaging and multi-wavelength near-infrared fluorescence. Leading camera manufacturers have integrated indocyanine green fluorescence modes directly into standard laparoscopic and robotic camera heads, eliminating the need to exchange optical scopes during surgery. By administering intravenous or biliary fluorescent dyes, surgeons can visually assess microvascular perfusion in real time prior to performing intestinal anastomoses and fluorescently illuminate extrahepatic bile ducts during complex cholecystectomies. This optical capability has dramatically lowered the incidence of accidental common bile duct transections and post-operative anastomotic breakdown, establishing near-infrared fluorescence imaging as a mandatory procurement requirement for next-generation hospital laparoscopic towers.
Furthermore, robotic endoluminal navigation has established itself as an indispensable clinical modality in interventional pulmonology, while expanding into gastrointestinal surgery. Between 2024 and 2026, leading thoracic oncology centers deployed shape-sensing robotic bronchoscopy platforms to access peripheral pulmonary nodules identified during low-dose CT cancer screenings. These robotic platforms provide continuous catheter stabilization, allowing pulmonologists to execute transbronchial cryobiopsies and microwave ablations of early-stage lung malignancies with unprecedented spatial precision. Concurrently, medtech conglomerates are advancing robotic endoluminal platforms equipped with flexible micro-instruments capable of executing bimanual dissection, full-thickness resection, and endoluminal suturing through natural orifices, paving the way for scarless endoluminal surgery.
Conclusion
The U.S. Endoscopy Devices Market Size & Share is positioned to expand from USD 16.64 billion in 2026 to approximately USD 26.85 billion by 2032, supported by a 8.31% CAGR from 2027 to 2032. Historical market development from USD 13.12 billion in 2023, USD 14.18 billion in 2024, and USD 15.35 billion in 2025 underscores the structural durability, capital resilience, and high procedural necessity of endoscopic medical technology across American healthcare systems.
The market’s long-term expansion is anchored in powerful demographic and clinical tailwinds. The aging of the U.S. population, expanding Medicare eligibility, and the institutionalization of early cancer screening programs—highlighted by the lowering of the colorectal cancer screening age to 45—ensure steady, growing patient caseloads across gastrointestinal, urological, pulmonary, and orthopedic clinical disciplines. Minimally invasive diagnostic and interventional endoscopy remains a primary clinical modality for reducing patient surgical trauma, shortening hospitalization intervals, and lowering overall episode-of-care costs.
The commercial landscape is defined by the ongoing transformation of device architecture, infection control paradigms, and surgical sites of care. The persistent challenges of manual scope reprocessing, heightened regulatory scrutiny from the FDA, and stringent AAMI ST91 standards have permanently established single-use and hybrid endoscopes as core clinical instruments, particularly in high-risk duodenoscopy, urgent bronchoscopy, and fragile ureteroscopy applications. Simultaneously, the structural migration of elective surgical and diagnostic procedures to ambulatory surgery centers and specialized outpatient clinics necessitates versatile, compact, energy-efficient visualization systems and high-throughput automated reprocessing infrastructure designed for rapid operating room turnover.
Visualization systems will continue their migration toward native 4K UHD resolutions, wide color gamuts, and solid-state LED illumination, augmented by indocyanine green near-infrared fluorescence imaging that enhances intraoperative tissue perfusion and biliary mapping. Edge artificial intelligence is becoming standard across video processor consoles, providing automated polyp detection and real-time lesion characterization that standardizes diagnostic precision across clinical operators. In parallel, advanced robotic-assisted endoluminal platforms and needle-arthroscopy systems are expanding the reach of minimally invasive medicine, enabling precise peripheral lung nodule biopsies and outpatient office-based joint inspections.
Geographically, the South will maintain absolute market revenue leadership, propelled by dense population centers, high retiree in-migration, and massive corporate healthcare systems across Texas and Florida. The West will maintain the fastest growth velocity through 2032, driven by California’s rapid clinical technology adoption, strong integrated health networks, and rigorous infection prevention standards. The Midwest will provide a deeply resilient foundation of capital equipment procurement across prestigious academic medical systems and high-volume surgical hospitals, while the Northeast will remain the country’s most evidence-driven and scientifically exacting regional market, anchored by premier teaching hospitals and clinical research centers.
For medical device manufacturers, hospital administrators, institutional investors, and healthcare supply chain leaders, competitive leadership through 2032 will belong to enterprises that deliver comprehensive, interconnected clinical ecosystems. Physical device excellence must be paired with intelligent software diagnostics, seamless enterprise electronic medical record and PACS connectivity, flexible capital financing options, and validated infection prevention profiles. Companies that successfully align their product portfolios with clinical workflow economics, ambulatory migration patterns, and patient safety imperatives will define the standard of care across the expanding U.S. endoscopy devices landscape.